BITTREX-GLOBAL-GMBH
19.4.2022 09:03:08 CEST | Business Wire | Press release
Bittrex Global , a leading digital asset exchange, today welcomes the YellowHeart Protocol, an NFT platform poised to disrupt the ticketing and music industries, to its Initial Exchange Offering (IEO) platform, Bittrex Global Starting Block.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005320/en/
By using blockchain technologies, the YellowHeart Protocol is transforming what tickets can do and how they are created, sold and resold. Through the protocol, tickets are now offered as non-fungible tokens (NFTs) and enhanced with new capabilities enabled by the HRTS (pronounced “Hearts”) utility token. In contrast to traditional tickets, NFT tickets offer music, video, and engaging experiences. They enable artists to communicate directly with their fans and provide artists and venues with a share of the proceeds any time a ticket is resold.
The YellowHeart Protocol was created to bring together an entire ecosystem – composed of fans, artists, sports teams, brands, venues, event promoters, and more – to participate in this leap forward. This community comes together at the YellowHeart NFT marketplace, which can be accessed online at yh.io or via the YellowHeart mobile app for iOS and Android.
"In addition to ticket NFTs, the YellowHeart marketplace also offers music NFTs, collectible NFTs and community NFTs. It is already the premier place for musicians to participate in the NFT revolution, where artists like Maroon 5, The Beatles and XXXTentacion are being joined by a rapidly growing community of creators. With the launch of the HRTS token anyone can now join this community; HRTS token holders will be able to engage with each other in innovative ways, creating a decentralized, peer-to-peer platform for ticketing and entertainment. We are proud to be the YellowHeart ecosystem’s founding member and technology provider,” said Josh Katz, founder and CEO of YellowHeart LLC.
“We are pleased to have selected YellowHeart as the first project to be launched on Starting Block. It displays strong signs of promise in the new world of Web 3 ticketing and music, and we are happy to support and generate more awareness around this project through our IEO platform,” said Stephen Stonberg, CEO of Bittrex Global.
“After our team drove an exhaustive, multi-month IEO qualification process, HRTS was selected as the first project to debut on Starting Block for many reasons, including the quality of its token utility value, fully-diluted valuation, circulating supply and demand balance, product roadmap, team experience, brand, and partner accomplishments. We’re excited for the future of the YellowHeart Protocol and think the addition of the HRTS token to the Bittrex Global ecosystem will add significant value for all of our users, especially for those who are lucky enough to get into the IEO,” said Chris Sinkey, Listing Director and Chief Business Officer at Bittrex Global.
Emerging projects looking to IEO can utilize and leverage Bittrex Global’s reputation as one of the most secure digital asset exchanges in the world, committed to using advanced security protocols while remaining compliant with the wide range of regulatory measures across the globe.
The YellowHeart Protocol (HRTS) token sale will launch at 13:00 UTC on May 10, 2022 on Bittrex Global Starting Block.
Learn more: https://global.bittrex.com/Market/Index?MarketName=USDT-HRTS
Disclaimer:
This release is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933. Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the issuer or selling security holder and that would contain detailed information about the issuer, as well as financial statements. There is no present intention to register any part of the present or proposed offering in the United States.
ABOUT YELLOWHEART PROTOCOL
The YellowHeart Protocol uses blockchain and NFT technologies to disrupt the ticketing industry and transform how artists and fans connect.
YellowHeart LLC is the technology provider and launch partner for the YellowHeart platform. Its marketplace for ticket NFTs, music NFTs, and community tokens attracts premier artists such as the Kings of Leon, Maroon 5, XXXTentacion, Brandi Carlile, ZHU, and more.
ABOUT BITTREX GLOBAL
Bittrex Global, the most secure digital asset exchange in the world, serves both retail and institutional clients, globally. Committed to helping users build wealth, Bittrex Global facilitates the purchase and trade of over 250 tokens. Through its use of cutting-edge technology, advanced security protocols, and a sophisticated elastic multi-stage wallet strategy the company provides a high-level experience for professional and novice customers alike. Bittrex Global is a key player in driving widespread adoption of secure and decentralized methods to building wealth while remaining compliant and adhering to the wide array of regulatory measures across the globe.
Bittrex Global GmbH is registered with the Financial Market Authority under Law of 3 October 2019 on Tokens and TT Service Providers (TVTG) in Liechtenstein to operate as a TT Exchange Service Provider, TT Token Depositary, and Token Issuer on behalf and for the account of third parties. Bittrex Global (Bermuda) Limited is regulated by the Bermuda Monetary Authority and licensed as a Class F Digital Asset Business under the Bermuda Digital Asset Business Act 2018 to operate as a digital asset exchange, provide custodial wallet services, and operate as a digital asset derivative exchange provider.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005320/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom